Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate

For biopharma R&D and regulatory strategy teams, the CNN investigation is a warning that dose selection, not just efficacy, will define the next oncology market battles. The report highlights Indian oncologists using one-twelfth of Opdivo's labeled dose with strong impact across several cancers, a finding that, if confirmed in rigorous trials, could disrupt per-patient revenue assumptions for PD-1 inhibitors while expanding access. With FDA's Project Optimus already pushing dose optimization, the case of economist Chuck Manski underscores why sponsors must generate robust pharmacokinetic, pharmacodynamic, and randomized lower-dose evidence earlier in development.

CNN's August 19, 2026 investigation into cancer drug dosing has crystallized a long-simmering challenge to FDA-approved oncology protocols. The story centers on Chuck Manski, a Northwestern University economist and advanced melanoma patient, who in 2022 stopped nivolumab (Opdivo) after six months of monthly infusions despite the FDA label calling for a full year. Manski developed permanent thyroid damage requiring lifelong medication and severe dryness in his eyes, lips, and mouth; his oncologist, when asked why the protocol specified a year, replied that it was FDA-approved "so that's what we use." With no cancer symptoms or signs by that point and after reviewing the medical literature, Manski concluded the intense side effects meant the treatment had largely run its course. He said, "So I made my own diagnosis. I took myself off."

“

The story centers on Chuck Manski, a Northwestern University economist and advanced melanoma patient, who in 2022 stopped nivolumab (Opdivo) after six months of monthly infusions despite the FDA label calling for a full year.

Manski's decision is not an outlier. The CNN report documents that oncologists in Canada, Israel, Sweden, and other countries already give nivolumab (Bristol Myers Squibb's Opdivo) and pembrolizumab (Merck's Keytruda) at lower doses, for shorter periods, or at longer intervals than the FDA recommended. In India, oncologists found that as little as one-twelfth of the labeled dosage of nivolumab had a powerful impact on several cancers. This real-world variation, coupled with the absence of dose-optimization data for many cancer drugs, has spawned an informal but determined community of researchers, doctors, and patients pushing for extra studies to identify the right dose and duration. The stakes are both clinical and financial: the article notes these approaches could save billions of dollars in cancer drug spending while sparing patients unnecessary toxicity.

Against the regulatory context, the controversy aligns with broader efforts by FDA's Oncology Center of Excellence, known as Project Optimus, to require dose-finding and optimization earlier in oncology development. Historically, chemotherapy dosing emphasized maximum tolerated dose, but for immunotherapies and targeted agents, lower doses can maintain efficacy with better tolerability. The Manski case exposes an information gap: patients and community oncologists often lack biomarkers, pharmacokinetic data, or decision-support tools to know when a drug has achieved its benefit. The fact that a health economist had to make his own diagnosis underscores how far oncology practice is from evidence-based personalization, even for top-selling drugs.